An Integrative Multi-Omic Biomarker Panel Distinguishes Hepatocellular Carcinoma From Chronic Liver Disease in HBV-Predominant Populations
In brief
Six-marker blood panel detected 88% of liver cancers with 94% specificity
In an independent validation set, the panel detected 88.4% of hepatocellular cancers while correctly ruling out cancer in 93.8% of people with chronic liver disease. It combined four DNA methylation markers and two proteins, and detected early-stage cancers more often than two established blood markers; prospective testing in surveillance populations is still needed before clinical use.
- Journal
- Hepatology research : the official journal of the Japan Society of Hepatology (Q1)
- Published
- 16 October 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Hao Zhuang, Xiaopei Hao, Tingting Zhang, Deqiang Li, Guanghao Li, Zhongyi Li, et al.
- PMID
- 42888887
- DOI
- 10.1111/hepr.70274
Why clinicians should know about it
- Picked for Biochemistry (medical) (paper of the day, 18 October 2026): Multi‑omic HCC biomarker panel
Abstract
AIM: DNA methylation is a promising diagnostic biomarker for various cancers including hepatocellular carcinoma (HCC). We aimed to identify aberrant DNA methylation and protein alterations via integrated approaches and develop a highly predictive biomarker panel for blood-based discrimination of HCC from non-HCC chronic liver disease (CLD) in an HBV-predominant population. METHODS: Genome-wide methylation profiling was conducted to screen hypermethylated CpG sites and genes distinguishing 55 HCC and matched non-HCC tissues. Candidate marker genes were then evaluated with five protein markers in 299 blood samples, and a diagnostic model was developed and validated in an independent cohort of 149 participants. RESULTS: Methylation pattern analysis identified 44 candidate hypermethylation biomarkers using four strategies. Through cross-validation, a panel of six methylation markers from four different groups yielded an AUC of 0.938, surpassing other methylation marker panels. A logistic regression model incorporating four DNA methylation markers and two protein markers achieved sensitivities of 91.8% and 88.4% at specificities of 95.4% and 93.8% in the training and validation sets, respectively. The 6-marker panel showed higher sensitivity of 82.9% for BCLC 0-A HCC, outperforming alpha-fetoprotein (AFP), and des-gamma-carboxyprothrombin (DCP). CONCLUSIONS: The developed 6-marker model demonstrated strong diagnostic performance for distinguishing HCC from non-HCC CLD in the studied HBV-predominant cohorts. It outperformed AFP and DCP in this case-control setting and may have potential for blood-based HCC detection. Prospective validation in surveillance cohorts is required before clinical implementation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.